In sharp contrast, a few of the enrolled non-APL AML patients demonstrated equivalent intensity of CD64 (9.1%, P < 0.001) with less and heterogeneous positive expression of CD13 (63.6%, P < 0.001) and/or CD33 (87.9%, P = 0.038). The gene discussed is CD33; the disease is acute myeloid leukemia.